A beta blocker blunted sleep apnea's heart-rate spikes, but cost some sleep quality
Researchers deliberately withdrew CPAP for three nights to simulate untreated sleep apnea, then tested propranolol against placebo. It slowed the heart-rate surges tied to apnea events, at the price of lighter sleep.
Obstructive sleep apnea repeatedly interrupts breathing during sleep, and each interruption is typically followed by a jolt of heart-rate acceleration — a pattern researchers believe contributes to the condition's cardiovascular risks. A trial published this month in Sleep and Breathing tested whether a common beta blocker, propranolol, could blunt that response, using a deliberate CPAP-withdrawal protocol to create a controlled window of untreated apnea [s1].
The design
The double-blind, randomized crossover study gave long-acting propranolol (80 mg) or placebo to people with obstructive sleep apnea, separated by a one-week washout period [s1]. To generate a period of measurable, untreated apnea in people who normally use CPAP, researchers used a three-night CPAP-withdrawal protocol — participants temporarily stopped their usual CPAP treatment under monitored conditions [s1]. Each drug or placebo dose was given at 6:30 PM, followed by overnight polysomnography (a full sleep study) and morning measurements of blood pressure, reactive hyperemia index, and augmentation index — two measures of blood vessel function [s1]. The primary outcome was heart rate; secondary outcomes covered heart-rate trajectory over time, sleep apnea severity, sleep architecture, blood pressure, and the two vascular measures [s1]. Twenty-one participants completed the study, with a mean age of 51 years, 62% male, and mean BMI of 33.8 kg/m² [s1].
What it found
Propranolol lowered mean overnight heart rate by 3.6 beats per minute compared with placebo (p < 0.001) [s1]. Broken down by phase of sleep, the drug reduced heart rate during stable sleep and specifically blunted the heart-rate accelerations that follow apneas, hypopneas, and arousals — the exact pattern the trial was designed to test [s1]. Morning diastolic blood pressure was also lower with propranolol [s1].
But the drug did not improve everything. Sleep apnea severity itself — measured independently of the heart-rate response — was unchanged by propranolol, as were systolic blood pressure and both measures of blood vessel function [s1]. And propranolol came with a cost to sleep quality: it reduced overall sleep efficiency and reduced the percentage of stage N2 sleep, a lighter but still restorative sleep stage [s1].
What this does and doesn't suggest
The trial's central finding — that a beta blocker can blunt the heart-rate surges associated with sleep apnea's respiratory events — targets a specific, plausible mechanism linking apnea to cardiovascular risk, since repeated heart-rate acceleration during sleep has independently been associated with mortality in people with sleep apnea, per background cited in the study [s1]. But propranolol did not reduce apnea severity itself, meaning it addresses one downstream consequence of untreated apnea rather than the underlying breathing disruption — CPAP or another apnea treatment still would be needed for that. And the sleep-quality trade-off — less efficient sleep, less N2 sleep — is a real cost that the trial documents alongside the cardiac benefit, not a clearly net-favorable result.
This is a mechanistic study in 21 people, using a temporary, monitored apnea-simulation protocol rather than long-term treatment. It doesn't test whether propranolol, taken over months or years alongside or instead of CPAP, changes cardiovascular outcomes like heart attack or stroke risk in people with sleep apnea. It also specifically studied people already diagnosed with and treated for sleep apnea, briefly taken off treatment — not untreated apnea as it exists in the wild.
Why it matters beyond this trial
The study's authors note a second use for the finding: many people with sleep apnea already take beta blockers for unrelated cardiovascular reasons, and this data may help clinicians interpret sleep-study results in those patients, since a beta blocker on board could mute the heart-rate signal that's normally used to gauge apnea severity or risk [s1].
What to watch
Longer trials testing whether blunting the heart-rate response translates into fewer cardiovascular events over time, and whether the sleep-quality cost persists or diminishes with continued use. This article describes results from a drug repurposing study; it is not medical advice, and starting or stopping beta blockers or CPAP therapy should not be done without a treating clinician.
Sources
- Propranolol mitigates sleep apnea-related cardiac responses during CPAP withdrawal: a randomized placebo-controlled cross-over clinical study — Sleep and Breathing, 11 March 2026
Sources
- Propranolol mitigates sleep apnea-related cardiac responses during CPAP withdrawal: a randomized placebo-controlled cross-over clinical study — Sleep and Breathing , March 11, 2026
More on
Patients with insomnia and apnea saw a bigger blood-pressure drop from CPAP
After four weeks, the comorbid-insomnia group's blood pressure fell 20 points more than the apnea-only group. The finding flips the usual framing of COMISA as simply a worse-outcomes phenotype.
A newer low-oxygen measure predicted disrupted blood pressure better than the standard
In 377 patients, hypoxic burden — a metric combining how often, how deep, and how long oxygen drops — tracked with abnormal nighttime blood pressure patterns where conventional measures didn't.
CPAP still outperforms mouth-guard alternatives, but the size of the gap is unclear
Pooling eight trials, oral appliances left nearly 12 more breathing events per hour than CPAP. But the trials disagreed with each other so much that the researchers say that number itself should be read with caution.
In heart patients with apnea but no sleepiness, CPAP still improved cardiac features
Nearly twice as many CPAP-treated patients saw their HFpEF-like markers improve at one year compared with those who went untreated — in a population sleep specialists have historically deprioritized for treatment.